Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Feb 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medical procedure called transbronchial cryobiopsy (TBLC) to see how effective and safe it is for diagnosing progressive pulmonary fibrosis (PPF). Progressive pulmonary fibrosis is a serious lung condition where lung tissue becomes scarred over time, making it hard to breathe. The trial aims to find out how this procedure affects patients' health, their treatment options, and overall healthcare costs. Participants will be randomly placed in one of two groups to receive either the TBLC or a different type of biopsy.

To be eligible for the trial, participants must be at least 18 years old and diagnosed with progressive pulmonary fibrosis or have a related lung condition. They should also have certain lung function test results that meet specific criteria. This trial is open to both men and women, and the researchers are currently looking for volunteers. If you join, you will undergo the TBLC procedure, and the team will monitor your health and progress throughout the study. This research could help improve the way doctors diagnose and treat pulmonary fibrosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg/m2.
• Exclusion Criteria:
• • Patients with platelet counts below 50,000×109/L or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC